MA51917A - Récepteurs antigéniques chimériques se liant à cd83 - Google Patents

Récepteurs antigéniques chimériques se liant à cd83

Info

Publication number
MA51917A
MA51917A MA051917A MA51917A MA51917A MA 51917 A MA51917 A MA 51917A MA 051917 A MA051917 A MA 051917A MA 51917 A MA51917 A MA 51917A MA 51917 A MA51917 A MA 51917A
Authority
MA
Morocco
Prior art keywords
chemerical
receptors binding
antigenic receptors
antigenic
binding
Prior art date
Application number
MA051917A
Other languages
English (en)
Inventor
Brian Betts
Marco Davila
Original Assignee
H Lee Moffitt Cancer Center & Res Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center & Res Institute Inc filed Critical H Lee Moffitt Cancer Center & Res Institute Inc
Publication of MA51917A publication Critical patent/MA51917A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051917A 2018-02-23 2019-02-22 Récepteurs antigéniques chimériques se liant à cd83 MA51917A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862634435P 2018-02-23 2018-02-23
US201862677783P 2018-05-30 2018-05-30

Publications (1)

Publication Number Publication Date
MA51917A true MA51917A (fr) 2021-06-02

Family

ID=67686942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051917A MA51917A (fr) 2018-02-23 2019-02-22 Récepteurs antigéniques chimériques se liant à cd83

Country Status (15)

Country Link
US (1) US20210032336A1 (fr)
EP (1) EP3755722A4 (fr)
JP (1) JP7358369B2 (fr)
KR (1) KR20200130324A (fr)
CN (1) CN112004832A (fr)
AU (1) AU2019226101A1 (fr)
BR (1) BR112020017015A2 (fr)
CA (1) CA3092220A1 (fr)
IL (1) IL276836A (fr)
MA (1) MA51917A (fr)
MX (1) MX2020008803A (fr)
PH (1) PH12020500632A1 (fr)
SG (1) SG11202007755YA (fr)
WO (1) WO2019165156A1 (fr)
ZA (1) ZA202005837B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544580A (ja) * 2019-08-16 2022-10-19 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 骨髄性悪性腫瘍を処置するためのキメラ抗原受容体
EP4013447A4 (fr) * 2019-08-16 2024-05-29 H Lee Moffitt Cancer Center & Res Institute Inc Récepteur antigénique chimérique anti-cd83 exprimant des lymphocytes t régulateurs
EP4041404A4 (fr) * 2019-09-30 2023-10-25 The Trustees of the University of Pennsylvania Anticorps anti-alpha-récepteur 4 de la famille des gdnf (grf-alpha-4) humanisé et récepteurs antigéniques chimériques (car)
US20230051885A1 (en) * 2019-12-18 2023-02-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and Methods for Producing Efficacious Regulatory T Cells
WO2021150970A1 (fr) * 2020-01-22 2021-07-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Lymphocytes t de récepteur antigénique chimérique bispécifique ciblant cd83 et le récepteur de l'interleukine 6
US20230107770A1 (en) * 2020-02-20 2023-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
US20230321239A1 (en) * 2020-08-14 2023-10-12 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor t cells for treating autoimmunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2013150592A (ja) * 2011-07-01 2013-08-08 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CN105531289B (zh) * 2013-02-01 2019-02-22 树突细胞生物科技有限公司 抗cd83抗体及其用途
AU2015336931B2 (en) * 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
AU2015338984A1 (en) * 2014-10-31 2017-04-27 The Trustees Of The University Of Pennsylvania Methods and compositions for modified T cells
US20160361360A1 (en) * 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US20200281973A1 (en) * 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore

Also Published As

Publication number Publication date
JP2021513857A (ja) 2021-06-03
WO2019165156A1 (fr) 2019-08-29
BR112020017015A2 (pt) 2020-12-15
ZA202005837B (en) 2023-02-22
CA3092220A1 (fr) 2019-08-29
IL276836A (en) 2020-10-29
MX2020008803A (es) 2021-01-15
US20210032336A1 (en) 2021-02-04
EP3755722A4 (fr) 2021-11-24
SG11202007755YA (en) 2020-09-29
CN112004832A (zh) 2020-11-27
EP3755722A1 (fr) 2020-12-30
JP7358369B2 (ja) 2023-10-10
PH12020500632A1 (en) 2021-05-10
AU2019226101A1 (en) 2020-09-17
KR20200130324A (ko) 2020-11-18

Similar Documents

Publication Publication Date Title
MA51734A (fr) Anticorps se liant à gprc5d
MA51917A (fr) Récepteurs antigéniques chimériques se liant à cd83
KR102355950B9 (ko) Tigit에 대한 항체
DK3440105T3 (da) T-cellereceptorer
DK3440106T3 (da) T-cellereceptorer
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3494133T3 (da) Anti-kras-g12d-t-cellereceptorer
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
DK3623386T3 (da) Agonistiske tnf-receptor-bindingsmidler
DK3201230T3 (da) Canine pd-l1-bindende pd-l1-antistoffer
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
DK3242892T3 (da) Modificerede april-bindende antistoffer
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3475303T3 (da) Anti-cd19-antistofformuleringer
DK3215530T3 (da) Forbedrede il-6 antistoffer
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
MA51302A (fr) Anticorps se liant à hla-a2/wt1
DK3236784T3 (da) Sammensætning omfattende en blanding af proteiner
DK3591122T3 (da) Hurtigskifter
MA49289A (fr) Anticorps se liant à steap-1